ABPI briefing on the Falsified Medicines Directive (FMD) OCT 2016
ABPI Conference 2016 - Richard Bergström on ''Work in partnership for better outcomes'
-
Upload
association-of-the-british-pharmaceutical-industry-abpi -
Category
Health & Medicine
-
view
121 -
download
0
Transcript of ABPI Conference 2016 - Richard Bergström on ''Work in partnership for better outcomes'
IMI
Working in partnership for better outcomes
Richard BergströmEFPIA Director General
ABPI Annual Conference, London, April 2016
ImpactOrganization
Outcomes focus has proven to deliver better outcomes at same or lower cost
Outcome
Cost
HC Value =
Examples with outcomes focus and increased HC value
1. Postoperative endophthalmitis 2. Swedish saving estimated based on US cost data
Patient. sat.
+20%
PE-rates1
-80%
Complic.
-21%
Mortality
-53%
Survival
+3%
NATIONELLA KATARAKTREGISTRET
Costs -25%
Costs2 -1%
Costs -28-36%
Costs-€515/pat.
Costs -6%
Where are we heading?
Pipelines are full (“no more me-toos”)
HTA: not a question of if, but of what patients and where are they?
Need to plan ahead
Value-based pricing meets budgets
Need capacity for deal-making, and tracking performance
Taking the life cycle perspective…
Over 7,000 researchers
59 public-private consortia
An international, cross-sector community
764 academicteams
146 SMEs
433 EFPIA teams
25 patient orgs
17 regulators
Integrated evidence
generation
Access Regulatory
7
Parallel Scientific & HTA advice
Early and continuous dialogue
PAES & PASS
Conditional marketing
authorisation
Full marketing authorisation (evt.
Subject to conditions)
PRIME
REA/HTA
Early patient access: combination of existing and new tools within the current legal framework
MEAs
Pricing/Reimburseme
nt
ADAPT SMART
Patient preference
elicitation for B/R
Adaptive Pricing – managing
uncertainties
RWE and Health
Outcomes
GetReal
Accelerated assessment (and decision making)
Compassionate Use/Early access
schemes
Dealing with disruption – national level dialogue needs to seek new solutions for the introduction of major high-value innovations
Medium
Med
ium
Rel
ativ
e Va
lue
Hig
hLo
w
HighLow
Budget Impact
New solutions needed!
Clear the way
Likely focus on managed entry agreements/ adaptive
approaches
“The trouble with some new innovations is that even though they may be cost effective, the budget impact is so high that the system can’t cope” NICE (at a recent EU meeting on
pricing and reimbursement)
Planning budgeting and horizon scanning processes are variable around Europe
Often budget impact of major innovations is uncertain before launch (and in the early post launch period)
Lack of solution can lead to ‘payer panic’ and an focus on prices that have a strong VFM case
How to smooth market entry?
Unlikely to get used!
9